• Shopping Cart
    There are no items in your cart

CLSI C62 A : 1ED 2014

Superseded

Superseded

A superseded Standard is one, which is fully replaced by another Standard, which is a new edition of the same Standard.

View Superseded by

LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY METHODS

Superseded date

07-07-2022

Superseded by

CLSI C62 A:2022

Published date

24-08-2018

Sorry this product is not available in your region.

Abstract
Committee Membership
Foreword
1 Scope
2 Standard Precautions
3 Terminology
4 Instrumentation
5 Preexamination Considerations
6 Assay Development
7 Assay Verification
8 Quality Assurance and Quality Control of Liquid
  Chromatography-Mass Spectrometry Assays
9 Postimplementation Monitoring
References
The Quality Management System Approach
Related CLSI Reference Materials

Gives guidance to the clinical laboratorian for the reduction of interlaboratory variance and the evaluation of interferences, assay performance, and other pertinent characteristics of clinical assays.

DocumentType
Miscellaneous Product
PublisherName
Clinical Laboratory Standards Institute
Status
Superseded
SupersededBy

This document provides an introduction to, and guidance for, method development, verification, and postimplementation monitoring of quantitative clinical applications using liquid chromatography-mass spectrometry (LC-MS). While LC-MS may also be used for qualitative analyses, the focus of this document is on the use of this technology for quantification of clinical analytes. In addition, while there are commercial and research methods that allow direct injection without chromatography for rapid analyses, this guideline is exclusively focused on liquid chromatography (LC) coupled to mass spectrometry (MS). The purpose of this guideline is to educate both clinical LC-MS practitioners and health care providers (including physicians) who may use these assays for patient care decisions on the benefits and limitations of LC-MS methods used in the clinical laboratory, as well as provide a practical guide for the development and implementation of LC-MS–based clinical applications. It is intended to serve not only as a companion to CLSI document C50,1 which serves as excellent general guidance for MS in the clinical laboratory, but also to provide an enhanced focus on methods, best practices, and instrumentation related to LC-MS, which is emerging as the most common approach to clinical analyses. This document is also intended to be a resource for instrument manufacturers, manufacturers of LC-MS reagents, regulatory agencies, and educators, as well as individuals responsible for developing laboratory standards and policy.

CLSI C52 : 3ED 2017 TOXICOLOGY AND DRUG TESTING IN THE MEDICAL LABORATORY

Access your standards online with a subscription

Features

  • Simple online access to standards, technical information and regulations.

  • Critical updates of standards and customisable alerts and notifications.

  • Multi-user online standards collection: secure, flexible and cost effective.